152 related articles for article (PubMed ID: 24620861)
1. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis.
Moreno E; Schwartz J; Fernández C; Sanmartín C; Nguewa P; Irache JM; Espuelas S
Expert Opin Drug Deliv; 2014 Apr; 11(4):579-97. PubMed ID: 24620861
[TBL] [Abstract][Full Text] [Related]
2. Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Carneiro G; Aguiar MG; Fernandes AP; Ferreira LA
Expert Opin Drug Deliv; 2012 Sep; 9(9):1083-97. PubMed ID: 22724539
[TBL] [Abstract][Full Text] [Related]
3. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation.
Schwartz J; Moreno E; Fernández C; Navarro-Blasco I; Nguewa PA; Palop JA; Irache JM; Sanmartín C; Espuelas S
Eur J Pharm Sci; 2014 Oct; 62():309-16. PubMed ID: 24964292
[TBL] [Abstract][Full Text] [Related]
4. A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations.
Abamor ES; Allahverdiyev AM
Exp Parasitol; 2016 Jul; 166():150-63. PubMed ID: 27109311
[TBL] [Abstract][Full Text] [Related]
5. Conventional formulations and emerging delivery systems for the topical treatment of Cutaneous Leishmaniasis.
Espuelas S
Ther Deliv; 2015 Feb; 6(2):101-3. PubMed ID: 25690078
[No Abstract] [Full Text] [Related]
6. Nano-based antileishmanial agents: a toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis.
Jebali A; Kazemi B
Toxicol In Vitro; 2013 Sep; 27(6):1896-904. PubMed ID: 23806227
[TBL] [Abstract][Full Text] [Related]
7. Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.
Van Bocxlaer K; Gaukel E; Hauser D; Park SH; Schock S; Yardley V; Randolph R; Plattner JJ; Merchant T; Croft SL; Jacobs RT; Wring SA
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507073
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies.
Santos CM; de Oliveira RB; Arantes VT; Caldeira LR; de Oliveira MC; Egito ES; Ferreira LA
J Biomed Nanotechnol; 2012 Apr; 8(2):322-9. PubMed ID: 22515084
[TBL] [Abstract][Full Text] [Related]
9. Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis.
Lalatsa A; Statts L; Adriana de Jesus J; Adewusi O; Auxiliadora Dea-Ayuela M; Bolas-Fernandez F; Dalastra Laurenti M; Felipe Domingues Passero L; Serrano DR
Int J Pharm; 2020 Oct; 588():119734. PubMed ID: 32777535
[TBL] [Abstract][Full Text] [Related]
10. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
11. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
Garnier T; Brown MB; Lawrence MJ; Croft SL
J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
[TBL] [Abstract][Full Text] [Related]
12. Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice.
Moreno E; Schwartz J; Larrea E; Conde I; Font M; Sanmartín C; Irache JM; Espuelas S
Nanomedicine; 2015 Nov; 11(8):2003-12. PubMed ID: 26282379
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B-loaded deformable lipid vesicles for topical treatment of cutaneous leishmaniasis skin lesions.
Carvalheiro M; Vieira J; Faria-Silva C; Marto J; Simões S
Drug Deliv Transl Res; 2021 Apr; 11(2):717-728. PubMed ID: 33534106
[TBL] [Abstract][Full Text] [Related]
14. Strategies for the design of orally bioavailable antileishmanial treatments.
Pham TT; Loiseau PM; Barratt G
Int J Pharm; 2013 Sep; 454(1):539-52. PubMed ID: 23871737
[TBL] [Abstract][Full Text] [Related]
15. Lipid-Based Nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer Management.
Simoes S; Carvalheiro M; Gaspar MM
Curr Pharm Des; 2016; 22(43):6577-6586. PubMed ID: 27396598
[TBL] [Abstract][Full Text] [Related]
16. Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro.
Allahverdiyev AM; Abamor ES; Bagirova M; Baydar SY; Ates SC; Kaya F; Kaya C; Rafailovich M
Exp Parasitol; 2013 Sep; 135(1):55-63. PubMed ID: 23792003
[TBL] [Abstract][Full Text] [Related]
17. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
18. Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.
Franco AM; Grafova I; Soares FV; Gentile G; Wyrepkowski CD; Bolson MA; Sargentini É; Carfagna C; Leskelä M; Grafov A
Int J Nanomedicine; 2016; 11():6771-6780. PubMed ID: 28008252
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study.
Soto JM; Toledo JT; Gutierrez P; Arboleda M; Nicholls RS; Padilla JR; Berman JD; English CK; Grogl M
Am J Trop Med Hyg; 2002 Feb; 66(2):147-51. PubMed ID: 12135285
[TBL] [Abstract][Full Text] [Related]
20. Topical treatment for cutaneous leishmaniasis.
Garnier T; Croft SL
Curr Opin Investig Drugs; 2002 Apr; 3(4):538-44. PubMed ID: 12090720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
